Oral Anticancer Therapy: Management of Drug Interactions-Reference-Cited by-同舟云学术

Oral Anticancer Therapy: Management of Drug Interactions

Published:2019-02 Issue:2 Volume:15 Page:81-90
ISSN:1554-7477
Container-title:Journal of Oncology Practice
language:en
Short-container-title:JOP

Author:

Rogala Britny G.¹,Charpentier Margaret M.¹,Nguyen Michelle K.²,Landolf Kaitlin M.³,Hamad Lamya⁴,Gaertner Kelly M.⁵

Affiliation:

1. University of Rhode Island, Kingston, RI

2. New York-Presbyterian Hospital, New York

3. UPMC Presbyterian, Pittsburgh, PA

4. Roswell Park Cancer Institute, Buffalo, NY

5. Allegheny Health Network, Pittsburgh, PA

Abstract

Oral anticancer therapy is increasingly integrated into the care of patients with cancer. Recognition and management of drug-drug interactions (DDIs) is critical to providing efficacious and safe anticancer treatment. DDIs with QTc-prolonging agents, anticoagulants, enzyme inducers and inhibitors, antidepressants, and acid suppressants are commonly encountered with anticancer therapies. Here, we review frequently observed DDIs and outline literature-supported suggestions for their management.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Health Policy,Oncology (nursing),Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JOP.18.00483

Reference56 articles.

1. NCCN Task Force Report: Oral Chemotherapy

2. Adherence to Oral Anticancer Medications: Evolving Interprofessional Roles and Pharmacist Workforce Considerations

3. Potential Obstacles in the Acquisition of Oral Anticancer Medications

4. Drug interactions in cancer therapy

5. Drug–drug interactions with tyrosine-kinase inhibitors: a clinical perspective

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Proton pump inhibitors decrease efficacy of palbociclib in patients with metastatic breast;Journal of Oncology Pharmacy Practice;2024-08-02

2. Use of a Smartphone Application to Promote Adherence to Oral Medications in Patients With Breast Cancer;JCO Oncology Practice;2024-07-26

3. Evaluation of oral targeted anticancer drug interactions and their management by oncology pharmacists;JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY;2024-04-30

4. Treatment adherence and adverse event management in chronic lymphocytic leukemia: challenges and strategies for the future;Expert Review of Clinical Pharmacology;2024-04-25

5. The Impact of Drug Interactions with Tyrosine Kinase Inhibitors on Adverse Event Development based on the changes of drug concentration level: Meta-analysis;Korean Journal of Clinical Pharmacy;2024-03-31